Predictors of Patient Engagement in Telehealth-Delivered Tobacco Cessation Treatment during the COVID-19 Pandemic.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Tobacco Use Cessation* ; Smoking Cessation* ; COVID-19*/epidemiology ; Telemedicine*; Male ; Humans ; Female ; Middle Aged ; Pandemics ; Patient Participation

Smoking causes one in three cancer deaths and may worsen COVID-19 outcomes. Telehealth tobacco cessation treatment is offered as a covered benefit for patients at the Stanford Cancer Center. We examined predictors of engagement during the COVID-19 pandemic. Data were abstracted from the Electronic Health Record between 3/17/20 (start of pandemic shelter-in-place) and 9/20/22, including patient tobacco use, demographics, and engagement in cessation treatment. Importance of quitting tobacco was obtained for a subset (53%). During the first 2.5 years of the pandemic, 2595 patients were identified as recently using tobacco, and 1571 patients were contacted (61%). Of the 1313 patients still using tobacco (40% women, mean age 59, 66% White, 13% Hispanic), 448 (34%) enrolled in treatment. Patient engagement was greater in pandemic year 1 (42%) than in year 2 (28%) and year 3 (19%). Women (41%) engaged more than men (30%). Patients aged 36-45 (39%), 46-55 (43%), 56-65 (37%), and 66-75 (33%) engaged more than patients aged 18-35 (18%) and >75 (21%). Hispanic/Latinx patients (42%) engaged more than non-Hispanic/Latinx patients (33%). Engagement was not statistically significantly related to patient race. Perceived importance of quitting tobacco was significantly lower in pandemic year 1 than year 2 or 3. Nearly one in three cancer patients engaged in telehealth cessation treatment during the COVID-19 pandemic. Engagement was greater earlier in the pandemic, among women, Hispanic/Latinx individuals, and patients aged 36 to 75. Sheltering-in-place, rather than greater perceived risk, may have facilitated patient engagement in tobacco cessation treatment.

Cancer Prev Res (Phila). 2019 Nov;12(11):735-740. (PMID: 31481540)
Am J Prev Med. 2022 Mar;62(3):341-349. (PMID: 34756629)
Nicotine Tob Res. 2021 May 4;23(5):866-871. (PMID: 33515223)
JCO Glob Oncol. 2021 Feb;7:311-323. (PMID: 33617304)
JCO Oncol Pract. 2022 May;18(5):e721-e730. (PMID: 34995104)
J Natl Compr Canc Netw. 2021 Nov;19(Suppl_1):S16-S20. (PMID: 34872053)
J Am Geriatr Soc. 2020 Nov;68(11):2431-2439. (PMID: 32930391)
Curr Oncol. 2019 Dec;26(6):361-368. (PMID: 31896934)
JAMA Intern Med. 2023 Apr 1;183(4):331-339. (PMID: 36848129)
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):617-9. (PMID: 17337647)
Respir Med. 2021 Jan;176:106237. (PMID: 33246296)
Oncologist. 2011;16(12):1784-92. (PMID: 22135122)
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2152-2155. (PMID: 32360185)
Eur J Public Health. 2014 Jun;24(3):433-9. (PMID: 24148557)
Implement Sci Commun. 2021 Apr 9;2(1):41. (PMID: 33836840)
J Natl Compr Canc Netw. 2016 Nov;14(11):1469-1477. (PMID: 27799514)
Age Ageing. 2007 Nov;36(6):638-43. (PMID: 17906305)
Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):261-70. (PMID: 8318879)
Int J Environ Res Public Health. 2020 Mar 22;17(6):. (PMID: 32235713)
Am J Prev Med. 2012 Jun;42(6):655-62. (PMID: 22608385)
Nicotine Tob Res. 2021 Aug 18;23(9):1617-1622. (PMID: 33782707)
BMJ Open. 2017 Nov 15;7(11):e018150. (PMID: 29146649)
N Engl J Med. 2019 Feb 7;380(6):512-515. (PMID: 30601710)
Head Neck. 2004 Mar;26(3):278-86. (PMID: 14999804)
Health Soc Care Community. 2006 Nov;14(6):572-82. (PMID: 17059499)
Health Equity. 2021 Jun 16;5(1):424-430. (PMID: 34235367)
J Psychoactive Drugs. 2021 Nov-Dec;53(5):483-490. (PMID: 34672862)
Prev Chronic Dis. 2020 Jan 30;17:E10. (PMID: 31999539)
Int J Environ Res Public Health. 2021 Feb 12;18(4):. (PMID: 33673207)
Am J Public Health. 2008 Feb;98(2):317-22. (PMID: 18172143)
Nicotine Tob Res. 2020 Aug 24;22(9):1446-1452. (PMID: 32236417)
Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286. (PMID: 27009521)
Eur Addict Res. 2021;27(4):242-256. (PMID: 33902030)
Adm Policy Ment Health. 2006 May;33(3):316-30. (PMID: 16598658)
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656. (PMID: 32399563)
Am J Prev Med. 2008 Aug;35(2):158-76. (PMID: 18617085)
Ann Surg Oncol. 2012 May;19(5):1430-8. (PMID: 22065194)
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S50-S58. (PMID: 31211105)
J Med Virol. 2021 Feb;93(2):1045-1056. (PMID: 32749705)
Addiction. 2015 Mar;110(3):381-6. (PMID: 25323093)

P30 CA1244351-13S2 National Cancer Institute Moonshot Initiative: Administrative Supplement for the P30 Cancer Center Support Grant to Develop Tobacco Cessation Treatment Capacity and Infrastructure for Cancer Patients

Keywords: COVID-19; cancer care; oncology; pandemic; quality improvement; smoking cessation; tobacco treatment

Date Created: 20240224 Date Completed: 20240226 Latest Revision: 20240227

20240227

PMC10887648

10.3390/ijerph21020131

38397622